A Conditional Marketing Authorisation (CMA) is a special form of EU marketing authorisation for medicinal products, whereby a medicine can be authorised on the basis of still incomplete clinical data if the expected benefit outweighs the risks and there is a high unmet medical need. The authorisation is tied to specific obligations that require missing evidence to be supplied after market entry within defined deadlines.
For patients, this means: an innovative medicinal product can become available earlier. For sponsors, it means: evidence generation is partly shifted to the post-market-entry phase and must be closely integrated with pharmacovigilance, medical affairs and quality management. Particularly in dynamic indications, it is essential to identify the remaining uncertainties transparently and to address them actively.
When is a conditional marketing authorisation an option?
Typical fields of application are severe or life-threatening diseases, rare conditions, or situations in which a medicinal product offers a substantial advance over existing therapies. This frequently concerns oncology, infectious diseases or conditions without an established standard therapy. Conditional marketing authorisation is thus an instrument for enabling earlier access without fundamentally abandoning the requirements for quality, safety and efficacy.
The prerequisite is generally that the available data already plausibly support a positive benefit-risk assessment but do not yet reach the completeness of a standard authorisation. Evidence is often available from randomised trials with still limited follow-up, from surrogate endpoints, or from smaller populations. It follows that planning for the data still to be submitted must be robust from the outset.
Legal framework and the role of the EMA
The CMA is regulated in the EU in particular by Regulation (EC) No 507/2006 and is assessed under the centralised procedure by the European Medicines Agency (EMA) and the CHMP. Unlike a “full” authorisation, a CMA is initially time-limited (generally one year) and must be renewed regularly. On renewal, it is assessed whether the sponsor has fulfilled the specific obligations and whether the benefit-risk profile remains positive.
An important practical point: a CMA is not a “discount” on quality. CMC data, manufacturing control, pharmacovigilance and risk management must be robust because the product is used in routine care after authorisation. This applies, for example, to batch release, specifications, stability data, and the ability to manage manufacturing changes in a controlled manner. In addition, the product information must consistently reflect the available data and remaining uncertainties.
Specific Obligations: studies and further evidence after authorisation
The core of the CMA is Specific Obligations. These frequently include additional clinical studies (e.g. confirmatory trials), extended subgroup analyses, or real-world evidence programmes. Obligations relating to product quality, the stability data package, or process validation may also be included. The aim is to close the initial evidence gap in a planned and verifiable manner.
- Confirmatory trials: confirmation of efficacy and safety in a robust study design.
- Pharmacovigilance: intensified safety monitoring, potentially including PASS, signal management and updated safety reports.
- Risk minimisation: additional measures, training material, or controlled dispensing in defined settings.
For project teams, it is essential to translate obligations into a realistic programme: protocol design, recruitability, selection of investigational sites, data management, monitoring and analysis must be planned at an early stage. Delays in confirmatory trials are a frequent risk, because they can jeopardise renewals and the conversion into a standard authorisation.
In practice, “data readiness” is also a central topic: if a confirmatory trial is primarily based on late clinical endpoints, interim analyses, follow-up plans and data quality must be designed so that the required timepoints are genuinely met. Incomplete query resolution or protocol deviations can become highly relevant from a regulatory perspective here.
Distinction and operational implications for sponsor/CRO
The CMA is to be distinguished from authorisation under exceptional circumstances and from accelerated assessment procedures. Whereas under exceptional circumstances data generation may remain permanently limited, in the case of a CMA the expectation is that missing data can and should be submitted subsequently. An accelerated assessment can additionally be used but does not automatically change the type of authorisation.
Operationally, a CMA shifts parts of the development programme into the post-authorisation phase. This requires integrated study and lifecycle management, clear responsibilities and early planning of study start-up, endpoints and recruitment. At the same time, commercial supply and evidence-generating studies run in parallel, which makes governance, resource planning and quality management considerably more demanding.
Typical mistakes are unclear endpoint definitions, overly optimistic timelines, or insufficient resources for parallel “commercial readiness”. Best practice is a coherent evidence plan and clear governance. For CRO teams, this often means that post-authorisation studies are managed like pivotal marketing authorisation trials, because they have a direct impact on authorisation status.
Regulatory references (selection)
- Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use.
- Regulation (EC) No 726/2004 (centralised procedure, role of the EMA).
- ICH E9 (statistical principles) and ICH E6(R3) (GCP requirements for trial conduct and data quality).
FAQ
How long is a Conditional Marketing Authorisation valid?
Generally, the CMA is initially valid for one year and is extended as part of a renewal, as long as the obligations are fulfilled and the benefit continues to outweigh the risks.
What are the consequences if obligations are not fulfilled?
If Specific Obligations are not fulfilled on time or not sufficiently, the EMA can refuse the renewal, tighten obligations, or suspend or revoke the authorisation. Operationally, this poses supply and reputational risks.
Can a CMA be converted into a “full” marketing authorisation?
Yes. Once the required additional data are available and a complete benefit-risk profile has been demonstrated, the CMA can be converted into a standard marketing authorisation.